Can Fite BioPharma Ltd (CANF)

[midastouch017]

Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®


https://finance.yahoo.com/news/fite-biopharma-interview-air-bloomberg-110000034.html

Fri, March 19, 2021, 1:00 PM

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced an interview with CEO Dr. Pnina Fishman will air on The RedChip Money Report® on the Bloomberg Network in the U.S. on Saturday, March 20th, at 7 p.m. local time in 73M homes across the United States. The RedChip Money Report also airs on Bloomberg International in Europe in 100M homes at 6 pm local time on Sundays.

In the exclusive interview, Dr. Fishman discusses the Company’s upcoming milestones, updates on the pipeline of proprietary small molecule drugs addressing inflammatory, cancer and liver diseases.

To view the interview segment, please visit:

"The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

About Piclidenoson

Piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies. It is currently being evaluated in a multinational Phase III study as a treatment for moderate to severe psoriasis and a Phase II U.S. study for the treatment of moderate to severe COVID-19.